CHEMELLO, LILIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.364
AS - Asia 5.391
EU - Europa 3.928
AF - Africa 1.655
SA - Sud America 1.497
OC - Oceania 172
Continente sconosciuto - Info sul continente non disponibili 87
Totale 26.094
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.551
SG - Singapore 1.588
CN - Cina 1.042
BR - Brasile 959
HK - Hong Kong 946
FI - Finlandia 527
DE - Germania 510
PL - Polonia 407
IT - Italia 317
VN - Vietnam 284
SE - Svezia 245
FR - Francia 169
UA - Ucraina 165
RU - Federazione Russa 164
GB - Regno Unito 113
AR - Argentina 84
TR - Turchia 83
IE - Irlanda 82
AT - Austria 79
IN - India 74
ZA - Sudafrica 74
NL - Olanda 73
IQ - Iraq 67
EC - Ecuador 66
PE - Perù 66
MX - Messico 65
MA - Marocco 62
NP - Nepal 62
CO - Colombia 61
CI - Costa d'Avorio 58
PY - Paraguay 56
MN - Mongolia 54
DZ - Algeria 53
ES - Italia 53
SI - Slovenia 53
UZ - Uzbekistan 53
MK - Macedonia 52
BZ - Belize 51
CZ - Repubblica Ceca 51
NO - Norvegia 51
SA - Arabia Saudita 51
TT - Trinidad e Tobago 51
AE - Emirati Arabi Uniti 50
JO - Giordania 50
JP - Giappone 50
KG - Kirghizistan 50
LB - Libano 50
GT - Guatemala 49
ID - Indonesia 49
LC - Santa Lucia 49
PS - Palestinian Territory 48
RO - Romania 48
TN - Tunisia 48
AO - Angola 47
ZM - Zambia 47
BE - Belgio 46
DO - Repubblica Dominicana 46
EG - Egitto 46
GM - Gambi 46
JM - Giamaica 46
PK - Pakistan 46
AL - Albania 45
KR - Corea 45
CL - Cile 44
CW - ???statistics.table.value.countryCode.CW??? 44
GN - Guinea 44
IL - Israele 44
ZW - Zimbabwe 44
BG - Bulgaria 43
ET - Etiopia 43
GR - Grecia 43
MZ - Mozambico 43
PR - Porto Rico 43
SO - Somalia 43
AU - Australia 42
BF - Burkina Faso 42
CV - Capo Verde 42
IS - Islanda 42
MG - Madagascar 42
MW - Malawi 42
VE - Venezuela 42
AZ - Azerbaigian 41
BO - Bolivia 41
CG - Congo 41
MD - Moldavia 41
MU - Mauritius 41
PA - Panama 41
CH - Svizzera 40
KE - Kenya 40
ML - Mali 40
NI - Nicaragua 40
YE - Yemen 40
BB - Barbados 39
HR - Croazia 39
KZ - Kazakistan 39
LV - Lettonia 39
SK - Slovacchia (Repubblica Slovacca) 39
UY - Uruguay 39
BY - Bielorussia 38
CA - Canada 38
Totale 24.201
Salva come PNG Salva come JPEG
Città #
Fairfield 1.641
Jacksonville 1.236
Woodbridge 945
Hong Kong 906
Singapore 875
Ashburn 861
Houston 858
Chandler 816
Wilmington 771
Cambridge 600
Seattle 538
Ann Arbor 472
Princeton 410
Boardman 389
Bytom 351
Medford 230
Santa Clara 208
San Diego 207
Nanjing 190
Beijing 185
Helsinki 181
Munich 121
Roxbury 118
Los Angeles 109
Ho Chi Minh City 82
São Paulo 80
Buffalo 79
Guangzhou 78
Dublin 75
Des Moines 74
Shenyang 66
Dong Ket 64
New York 61
Hebei 60
Nanchang 59
Hefei 54
Jiaxing 54
Chicago 53
Padova 52
Ulan Bator 52
Abidjan 51
Changsha 50
Tashkent 49
Amman 48
Castries 48
Vienna 48
Bishkek 46
Lusaka 45
Lima 44
Luanda 44
Norwalk 44
Hanoi 43
Conakry 42
Harare 40
Baku 39
Antananarivo 38
Bamako 38
Managua 37
Panama City 37
Turku 37
Willemstad 37
Bridgetown 36
Libreville 36
Nuremberg 36
Redondo Beach 35
Tianjin 35
Montevideo 34
Riga 33
Vientiane 33
Accra 32
Dushanbe 32
Jinan 32
Kampala 32
Maputo 32
Minsk 32
Addis Ababa 31
Cotonou 31
Lilongwe 31
Nairobi 31
Praia 31
Reykjavik 31
Dakar 30
Ouagadougou 30
Havana 29
Kigali 29
Ljubljana 29
Djibouti 28
Guatemala City 28
Nouakchott 28
Noumea 28
Skopje 28
Tbilisi 28
Andorra la Vella 27
Belize City 27
Kathmandu 27
Kingston 27
Milan 27
Nassau 27
Niamey 27
Pristina 27
Totale 16.353
Salva come PNG Salva come JPEG
Nome #
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 201
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. 182
Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. 182
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 177
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 175
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 168
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 166
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort 164
ANTIBODY TO THE POLYALBUMIN (pHSA) RECEPTOR ON HEPATITIS B VIRUS IN ACUTE INFECTION AND IN VACCINE RECIPIENTS 158
Liver stellate cells in chronic viral hepatitis : the effect of interferon therapy. 154
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 154
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 153
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 152
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 149
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 147
Kinetic of virological response during PEG-IFNs in chronic hepatitis C. 144
HEPATITIS C VIRUS SEROTYPES AND LIVER PATHOLOGY 144
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 142
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 141
HEPATITIS C VIRUS RNA PROFILES IN CHRONICALLY INFECTED INDIVIDUALS: DO THEY RELATE TO DISEASE ACTIVITY? 140
Acute hepatitis C virus infection in a nurse trainee following a needlestick injury 140
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 140
Profiles of HCV core protein and viremia in chronic hepatitis C: Possible protective role of core antigen in liver damage 138
Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. 138
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS 135
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C 134
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C 134
HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND HEPATITIS-C PATHOLOGY 132
Chronic evolution of acute hepatitis type B: prevalence and predictive markers 131
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 131
Prognostic value of liver and spleen stiffness in patients with fontan associated liver disease (Fald): A case series with histopathologic comparison 130
Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. 128
Serum hepatitis B virus DNA in acute hepatitis type B 127
A model to predict long-term sustained response to interferon therapy in chronic hepatitis C 126
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 124
Natural history of hepatitis C. 124
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 124
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 124
Therapy of hepatitis C: re-treatment with alpha interferon. 123
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. 123
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels 123
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 122
Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. 121
Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction 120
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 119
Surgical management of failing Fontan circulation: Results from 30 cases with 285 patient-years follow-up 119
OUTCOME OF ACUTE HEPATITIS C AND ROLE OF ALPHA INTERFERON THERAPY 118
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals 118
A COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS OF VARICEAL BLEEDING STARTING FROM SMALL ESOPHAGEAL VARICES COMPARED TO SURVEILLANCE AND TREATMENT STARTING FROM LARGE ONES 117
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa‐2A interferon 117
Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Analysis by polymerase chain reaction. 117
Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. 116
Liver Fibrosis and Steatosis in Alstrom Syndrome: A Genetic Model for Metabolic Syndrome 116
Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population 115
Alterazioni neurovascolari nell’epatite cronica C: uno studio caso-controllo 115
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. 114
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 113
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 111
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 111
Heart rate variability parallels changes in psychiatric scales in interferon-treated patients with chronic hepatitis. 110
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma 110
NATURAL KILLER ACTIVITY IN PATIENTS WITH ACUTE VIRAL HEPATITIS 109
RELATIONSHIP BETWEEN HBcAg IN SERUM AND LIVER AND HBV REPLICATION IN PATIENTS WITH HBsAg POSITIVE CHRONIC LIVER DISEASE 109
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 109
Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. 109
The cognitive effects of long-term interferon treatment for chronic viral hepatitis 108
The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence 107
Interferon-ribavirin combination therapy for chronic hepatitis C. 107
Chonic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. 107
Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals 107
PREDICTIVE MARKERS OF CHRONICITY IN ACUTE HEPATITIS TYPE B 106
METABOLIC SYNDROME INDUCES A MORE RAPID PROGRESSION OF FIBROSIS IN PRIMARY BILIARY CIRRHOSIS IN EARLY STAGE 106
Hepatitis C serotype and response to interferon therapy. 106
Comparison of thrice weekly vs daily human leucocyte interferon-alfa therapy for chronic hepatitis C. 105
SERUM HBV-DNA IN ANTI-HBE POSITIVE PATIENTS DETECTED BY FILTER AND LIQUID-PHASE HYBRIDIZATION ASSAYS 105
Anti-interferon antibodies during interferon therapy for chronic hepatitis C. 105
BIOLOGIA MOLECOLARE APPLICATA AL VIRUS DELL'EPATITE B. STUDIO DEL DNA VIRALE NEL SIERO E NEL FEGATO E CORRELAZIONE CLINICA 105
In-Hospital Screening Campaign Against Hepatitis C Could Be Effective for Identifying More Patients Who Still Need Treatment 104
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 104
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 104
ALTERAZIONI DELL'ATTIVITA' NATURAL KILLER IN CORSO DI INFEZIONE DA VIRUS EPATITICI 103
DEREGOLAZIONE DELL’ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) NEI LINFOCITI B IN PAZIENTI INFETTI DA HCV 103
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 103
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 102
EVIDENCE OF HEPATITIS B VIRUS INFECTION IN CHRONIC HEPATITIS HBsAg NEGATIVE BY CONVENTIONAL ASSAYS 102
Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. 101
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay. 101
COMPARISON OF THRICE WEEKLY VS DAILY HUMAN LEUCOCYTE INTERFERON-ALPHA THERAPY FOR CHRONIC HEPATITIS C. TVVH STUDY GROUP. 100
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 100
Monoclonal radioimmunoassay for hepatitis B surface antigen in sera of children with acute leukemia. 100
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 100
Monitoring SCCA-IgM complex predicts hcc development in cirrhotic patients 99
A cost-effectiveness analysis of prophylaxis of variceal bleeding starting from small esophageal varices compared to surveillance and treatment starting from large ones. 99
Validation of a new sonographic parameter (liver/kidney ratio of greys intensity of digital images) for diagnosis and quantification of liver steatosis 99
A MODEL TO PREDICT SUSTAINED RESPONSE TO THERAPY AND TO OPTIMIZE THE DOSE OF INTERFERON IN CHRONIC HEPATITIS C 99
CHRONIC HEPATITIS C WITHOUT ANTIBODY TO C-100 98
Neurotoxychological Monitoring of Interferon treatment in Viral Hepatitis: a Pilot Sudy 97
Changes in serum tryptophan during antiviral therapy with recombinant alfa-interferon in chronic hepatitis C 97
CLINICAL FEATURES AND RESPONSE TO INTERFERON IN PATIENTS WITH DIFFERENT HCV GENOTYPES IN ITALY 97
ANTIGENE CORE NEL SIERO .DETERMINAZIONE E SIGNIFICATO IN PAZIENTI CON INFEZIONE ACUTA E CRONICA DA VIRUS DELL'EPATITE B 97
Totale 12.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.861
article - articoli 63.303
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 667
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.040
Totale 149.871
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.485 0 0 0 111 49 255 37 149 330 154 174 226
2021/20222.678 42 481 200 241 78 150 112 262 139 52 305 616
2022/20231.972 600 160 62 145 315 233 8 115 194 23 100 17
2023/2024817 38 102 81 51 36 74 48 29 21 22 124 191
2024/20255.219 4 308 197 135 715 76 182 321 555 231 1.030 1.465
2025/20267.564 642 1.931 3.488 1.503 0 0 0 0 0 0 0 0
Totale 26.170